Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">STAAR Surgical target raised to $12 at The Benchmark Company (10.17)The Benchmark Company raises their STAA tgt to $12 from $10. Generally in-line Q4 results are superseded by the prospect in 2017 of exciting new products and the resolution of STAAR's longstanding FDA remediation/quality systems upgrade. This year, mgmt expects to introduce the EDOF EVO spheric optic ICL, and a preloaded ICL. In addition to these meaningful international product introductions, mgmt disclosed it has completed its planned FDA remediation and has engaged an outside consultant to perform an evaluation prior to requesting an FDA evaluation. <strong>Firm anticipates this is the prelude to U.S. Toric clearance, as well as follow-on products. Beyond the upside these products could represent to their model, firm believes they represent very substantial LT strategic value. Mgmt expects quality systems improvements to continue and plans for permanently elevated expense.</strong></td> </tr></table>"